ACXP News and Press, Acurx Pharmaceuticals Inc. From 08/12/25

2025-08-12 07:10:02 ET More on Acurx Pharmaceuticals Acurx Pharmaceuticals files $50M mixed shelf offering Seeking Alpha’s Quant Rating on Acurx Pharmaceuticals Historical earnings data for Acurx Pharmaceuticals Financial information for Acurx Pharmace...

Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , Aug. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical comp...

Reeds Inc. (REED) is expected to report $-0.04 for Q2 2025 Jerash Holdings (US) Inc. (JRSH) is expected to report for Q1 2026 Churchill Capital Corp IX (CCIX) is expected to report for quarter end 2025-06-30 Verde Clean Fuels Inc. (VGAS) is expected to report for Q2 2025 Mobile In...

Acurx Pharmaceuticals Inc. (ACXP) is expected to report $-2 for Q2 2025

Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split PR Newswire Acurx's common stock is expected to begin trading on a post-split adjusted basis on August 5, 2025 STATEN ISLAND, N.Y. , July 31, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (N...

Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , July 24, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Compa...

2025-07-09 17:45:34 ET More on Acurx Pharmaceuticals Acurx Pharmaceuticals, Inc. (ACXP) Q1 2025 Earnings Call Transcript Acurx signals progress in Phase 3 ibezapolstat program with $12M credit line following regulatory alignment Seeking Alpha’s Quant Rating on...

/C O R R E C T I O N -- Acurx Pharmaceuticals, Inc./ PR Newswire In the news release, Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds, issued 17-Jun-2025 by Acurx Pharmaceuticals, Inc. over PR Newswire, we have been advised by ...

Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds PR Newswire STATEN ISLAND, N.Y. , June 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical compa...

2025-06-17 07:37:10 ET DENVER, Colo., Jun 17, 2025 ( 247marketnews.com )- Acurx Pharmaceuticals (NASDAQ:ACXP) announced today the publication of positive Phase 2b clinical trial results for its lead candidate, ibezapolstat, in Lancet Microbe . The data highlight a 94% clinical c...